explore -WSS

explore

author：explore 2025-08-31 20:52:18 - browse：85

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： 10 million people disenrolled from Medicaid over past six months

WSS

Sanofi CEO defends move to abandon profit guidance, boost research

Excited delirium, Elijah McClain, and emergency physicians

Cancer, immunology, HIV research ensnared in fetal tissue politics

HPV cancer vaccine study demonstrates efficacy

Bring on the sabbaticals for nurses

Pregnancy ages women, but effects reverse after delivery

entertainment

explore

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

With Wegovy coverage, Medicare patients may face high costs

After affirmative action ruling, medical educators look to 'holistic review'

Senate panel clears PBM, hopsital reforms

Cancer drug shortages should be causing more outrage

Adam's Take: Intra

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Diabetes management: Digital health tools fall short, study says

Virginia high school admissions case could be legal follow

More doctors should go into startup world

hotspot

Cancer, immunology, HIV research ensnared in fetal tissue politics

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

A clever new way to fix Medicaid and graduate medical education

Free speech concerns arise in wake of journal editor Eisen's firing

Testing GLP

Sanofi CEO defends move to abandon profit guidance, boost research

focus

explore

hotspot

explore